Shots:

• The company will initiate the P-III trial to evaluate batoclimab (680/340mg) via weekly SC inj. in patients with MG. The company plans to start the trial in H1'22 & results are expected in 2024
• The trial is designed to include an induction period. Additionally, primary efficacy analysis will be based on MG-ADL as measured in acetylcholine receptor Ab positive patients @12wks., follow-on treatment with alternative dosing regimens will be evaluated in subsequent study periods, safety is generally consistent with those used in other similar programs
• Batoclimab is a fully human mAb targeting FcRn for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies

Ref: Globe Newswire | Image: Immunovant